Biotech Catalysts to Watch: Key Developments Ahead in Q4 2026

September 2026 brings several biotech catalysts into focus, such as Gossamer Bio's seralutinib (GB002) with a 58% probability of approval (PoA). Key regulatory dates are on the horizon, and investors should consider how these catalysts could influence stock performance and market trends.

The full biotech catalysts to watch

Gossamer Bio's Seralutinib (GB002) for Pulmonary Arterial Hypertension

Gossamer Bio plans to submit a New Drug Application (NDA) for seralutinib (GB002) in September 2026, targeting pulmonary arterial hypertension (PAH). The estimated probability of approval is 58%, indicating moderate risk. This inhaled small-molecule kinase inhibitor aims to address a significant unmet need in PAH, projected to reach an $8.57 billion market by 2026. The Phase 3 PROSERA study forms the core evidence for the NDA, with the FDA noting that statistical significance is a review issue, not a filing issue. While no major safety signals have emerged, the lack of detailed public safety data raises questions about tolerability and long-term safety. Gossamer's mixed history with the FDA adds complexity, marking this submission as crucial for the company.

BioXcel Therapeutics' IGALMI® (Dexmedetomidine) and Its Upcoming PDUFA

BioXcel Therapeutics anticipates a decision on IGALMI® (dexmedetomidine) for acute agitation treatment linked to bipolar disorders and schizophrenia by November 14, 2026. Already approved for these uses, the upcoming PDUFA likely concerns a supplemental NDA for Alzheimer’s-related agitation, based on the Phase 3 TRANQUILITY II trial. The probability of approval is just 10%, reflecting a high-risk scenario due to uncertainties about the new indication. Despite its status as a first-in-class sublingual film, cardiovascular safety concerns, especially in vulnerable groups, linger. The market for acute agitation treatments is vital, yet potential cardiovascular issues could limit clinical adoption despite promising trial data. This decision will be pivotal for BioXcel's efforts to broaden IGALMI's therapeutic scope.

Sionna Therapeutics' SION-451: A Phase 1 Trial with Low Approval Odds

Sionna Therapeutics is running a Phase 1 trial for SION-451, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, to be used with two proprietary CFTR correctors. The trial includes 144 healthy volunteers, focusing on safety and tolerability, with topline data expected soon. However, the probability of approval is only 18%, suggesting a low chance of success. The market size for this indication is effectively $0 since healthy volunteers aren't a disease population. This complicates the investment outlook, and applying findings from healthy subjects to cystic fibrosis patients presents challenges. The data release will be key to deciding on a Phase 2b trial.

Capricor Therapeutics' Deramiocel (CAP-1002) and Its PDUFA Date

Deramiocel (CAP-1002) is under FDA review, with a PDUFA date set for November 22, 2026. This allogeneic cell therapy targets Duchenne muscular dystrophy (DMD), focusing on the cardiomyopathy linked to the disease. The probability of approval is 42%, indicating moderate risk. The pivotal HOPE-3 trial supports the application, but concerns about the evidence presented to the advisory committee have introduced regulatory uncertainties. While the global DMD treatment market could reach about $3.8 billion by 2026, the strength of efficacy data is crucial for approval. The PDUFA decision will offer insights into the FDA’s perspective on novel cell therapies for rare diseases.

Additional Biotech Catalysts to Watch in Q4 2026

Looking ahead, several other biotech catalysts loom. In October 2026, Tiziana Life Sciences (TLSA) targets non-active secondary progressive multiple sclerosis with intranasal foralumab, although approval probability is low. MBX Biosciences (MBRX) will present data on Annamycin for relapsed or refractory acute myeloid leukemia in September 2026, also with a low PoA. In contrast, INO-3107 from Inovio Pharmaceuticals, targeting recurrent respiratory papillomatosis, has a high PoA and is expected to draw significant interest on its October 30, 2026, decision date. These catalysts highlight the dynamic nature of biotech innovation and underscore the need for investors to stay alert to upcoming regulatory decisions.

The bottom line

Approaching the final quarter of 2026, staying informed about these biotech catalysts will be essential for making informed investment decisions.